Erasca Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that, in connection with the appointment of Charles S. Fuchs, M.D., M.P.H., as president of research and development, Erasca’s Board of Directors has approved the grant of inducement awards.
The Board of Directors approved the grant to Dr. Fuchs of non-qualified stock options to purchase 1,278,520 shares of Erasca common stock under the company’s 2026 Employment Inducement Incentive Award Plan (the “Inducement Plan”), 25% of which will vest on August 10, 2027, and the remainder of which will vest in 36 equal monthly installments thereafter. The stock options were granted on August 10, 2026 with an exercise price equal to the closing price of Erasca’s common stock on the Nasdaq Global Select Market on the grant date.
The Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Erasca, or following a bona fide period of non-employment, as an inducement material to such individuals’ entering into employment with Erasca, pursuant to Nasdaq Listing Rule 5635(c)(4).
About Erasca
At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of patients with cancer. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.
Contact:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
Source: Erasca, Inc.
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
5 Stocks to Sell for Tax-Loss Harvesting
33 Undervalued Stocks to Buy Before the Market Shifts Again
What’s Ahead for Stocks This Quarter—and Where to Invest
Ask the Analyst: What Is the Best Source for Low-Risk Tax-Free Income?
United States